BioAge rais­es $170M as obe­si­ty spot­light shifts to oral op­tions, mus­cle pre­servers

BioAge Labs has reeled in the biotech in­dus­try’s largest pri­vate fi­nanc­ing round so far in 2024 as the Cal­i­for­nia start­up goes full throt­tle on the hottest ar­eas in obe­si­ty drug de­vel­op­ment: oral for­mu­la­tions and mus­cle preser­va­tion.

The biotech, which emerged as one of the an­ti-ag­ing play­ers in 2015, is mov­ing for­ward with aze­laprag, a drug it li­censed from Am­gen af­ter the phar­ma had at­tempt­ed de­vel­op­ing it for heart fail­ure. Its $170 mil­lion Se­ries D, dis­closed Tues­day morn­ing, is the 10th megaround (at least $100 mil­lion) of the year, per End­points News da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER